Sanofi, France's largest healthcare company, announced an investment of approximately 1 billion euros in Beijing to build the company's largest single investment project in China to date.

According to Bloomberg, multinational pharmaceutical company Sanofi announced on Monday (December 2, 2024) that it will invest approximately 1 billion euros to establish a new insulin production and manufacturing base in Yizhuang, Beijing. This will be Sanofi's fourth production and supply base in China and the second in Beijing. This base is expected to significantly enhance the local end-to-end production and manufacturing capabilities of insulin and serve the insulin medication needs of Chinese diabetic patients.